FDA Approves First Integrase Inhibitor, Raltegravir
On October 12, 2007, the FDA approved raltegravir for use with other antiretroviral agents in the treatment of HIV infection. Raltegravir is the first drug to be approved in a new class of anti-HIV agents known as integrase inhibitors. Drugs in this class block the HIV integrase enzyme, which inserts the genetic material of the HIV virus into the DNA of an infected cell.
More information about raltegravir is available:
Fall 2007 Issue of Mental Health AIDS Released
Mental Health AIDS is a quarterly biopsychosocial research update on HIV and mental health sponsored by the Center for Mental Health Services (CMHS) of the Substance Abuse and Mental Health Services Administration (SAMHSA). This publication is provided free of charge through the SAMHSA Web site in both PDF and HTML formats.
The Fall 2007 issue features the "Enlisting Service Consumers as Active Participants in HIV-Related Assessment & Care" Tool Box.
